新型粪便Lachnoclostridium标记物用于结直肠腺瘤和癌症的无创诊断
研究在1012名亚洲受试者中通过宏基因组学鉴定粪便细菌标记物,并采用定量PCR验证。发现Lachnoclostridium sp.的m3标记在腺瘤中显著富集,其诊断腺瘤的AUC为0.675,优于Fn的0.620,且与FIT联用可提高晚期腺瘤敏感性至56.8%。
要点
- 粪便m3标记物对结直肠腺瘤诊断有一定价值,AUC为0.675。
- m3诊断腺瘤敏感性48.3%优于Fn的33.8%(特异性78.5%)。
- m3与FIT联用可提高晚期腺瘤检出敏感性至56.8%。
核心结论
- 粪便Lachnoclostridium sp.的m3标记物可用于结直肠腺瘤的无创诊断。
研究设计与样本
- 研究纳入两个独立亚洲队列共1012名受试者(274例CRC、353例腺瘤、385例对照),通过宏基因组学鉴定候选标记物并用靶向定量PCR验证。
主要发现
- 在队列I(n=698)中粪便m3和Fn从正常到腺瘤到CRC显著增加(p<0.0001,单因素方差分析线性趋势),队列II(n=313)进一步证实(p<0.0001)。
- m3区分腺瘤与对照的AUC为0.675,Fn为0.620(p=0.09);Fn诊断CRC的AUC为0.862,m3为0.741(p<0.0001)。
- 在78.5%特异性下,m3和Fn对腺瘤的敏感性分别为48.3%和33.8%,对CRC的敏感性分别为62.1%和77.8%。
- 在FIT亚组(n=642)中,m3检测非进展期和进展期腺瘤的敏感性分别为44.2%和50.8%(特异性79.6%),FIT分别为0%和16.1%(特异性98.5%)。
- m3与FIT联用将进展期腺瘤敏感性提高至56.8%;m3联合Fn、Ch、Bacteroides clarus和FIT诊断CRC的敏感性93.8%、特异性81.2%。
临床怎么用
- m3可作为结直肠腺瘤无创诊断的候选粪便标记物,与FIT联用可能提高进展期腺瘤检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a need for early detection of colorectal cancer (CRC) at precancerous-stage adenoma. Here, we identified novel faecal bacterial markers for diagnosing adenoma. DESIGN: This study included 1012 subjects (274 CRC, 353 adenoma and 385 controls) from two independent Asian groups. Candidate markers were identified by metagenomics and validated by targeted quantitative PCR. RESULTS: Metagenomic analysis identified 'm3' from a Lachnoclostridium sp., Fusobacterium nucleatum (Fn) and Clostridium hathewayi (Ch) to be significantly enriched in adenoma. Faecal m3 and Fn were significantly increased from normal to adenoma to CRC (p<0.0001, linear trend by one-way ANOVA) in group I (n=698), which was further confirmed in group II (n=313; p<0.0001). Faecal m3 may perform better than Fn in distinguishing adenoma from controls (areas under the receiver operating characteristic curve (AUROCs) m3=0.675 vs Fn=0.620, p=0.09), while Fn performed better in diagnosing CRC (AUROCs Fn=0.862 vs m3=0.741, p<0.0001). At 78.5% specificity, m3 and Fn showed sensitivities of 48.3% and 33.8% for adenoma, and 62.1% and 77.8% for CRC, respectively. In a subgroup tested with faecal immunochemical test (FIT; n=642), m3 performed better than FIT in detecting adenoma (sensitivities for non-advanced and advanced adenomas of 44.2% and 50.8% by m3 (specificity=79.6%) vs 0% and 16.1% by FIT (specificity=98.5%)). Combining with FIT improved sensitivity of m3 for advanced adenoma to 56.8%. The combination of m3 with Fn, Ch, Bacteroides clarus and FIT performed best for diagnosing CRC (specificity=81.2% and sensitivity=93.8%). CONCLUSION: This study identifies a novel bacterial marker m3 for the non-invasive diagnosis of colorectal adenoma.
引用
- Liang JQ, Li T, Nakatsu G, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2019. PMID: 31776231. doi:10.1136/gutjnl-2019-318532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。